ACH

SEC Filing Summary: Owens & Minor, Inc. (10-Q)

Business Context and Reporting Period

This filing is a Quarterly Report on Form 10-Q for Owens & Minor, Inc. (O&M), a medical and surgical supply distributor, for the period ended September 30, 2005. The company operates primarily in the wholesale distribution of medical/surgical supplies and, following recent acquisitions, in the direct-to-consumer distribution of diabetic supplies. The report covers the three and nine months ended September 30, 2005, compared to the same periods in 2004.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 6% in the third quarter and 7% for the first nine months of 2005 compared to 2004. Approximately one-fourth of the Q3 increase was attributable to acquisitions (Access Diabetic Supply and Direct Diabetic Supplies).
• Margin Expansion: Gross margin improved to 10.9% in Q3 2005 from 10.1% in Q3 2004, driven by the higher-margin direct-to-consumer business acquired in January 2005. Operating earnings margin increased to 2.6% in Q3 from 2.4% in the prior year.
• Acquisitions: The company acquired Access Diabetic Supply, LLC for $58.8 million in cash in January 2005, and subsequently acquired assets of Direct Diabetic Supplies ($1.6 million) and Cyrus Medical Systems ($1.0 million) in April 2005. These transactions increased goodwill by approximately $38.5 million.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses as a percentage of revenue increased to 7.9% in 2005 from 7.4% in 2004, primarily due to the higher SG&A structure of the new direct-to-consumer segment.
• Capital Expenditures: Capital spending rose to $23.0 million for the first nine months of 2005 from $11.8 million in 2004, largely due to construction of a new corporate headquarters.

Outlook, Risks, and Contingencies

• Hurricane Impact: While facilities were undamaged by Hurricanes Katrina and Rita, the company incurred approximately $1 million in negative operating earnings impact due to lost sales and higher delivery costs. Management anticipates a continuing negative impact in Q4 2005.
• Tax Contingency: The IRS proposed disallowing certain LIFO inventory valuation reductions effective from 2001. If unsuccessful in its appeal, the company faces a potential tax deficiency of $40.9 million plus approximately $5.3 million in interest. Management believes its position is appropriate and has not established a reserve.
• Credit Rating: Standard & Poor's upgraded the company's corporate credit rating to BBB- (investment grade) from BB+ in Q3 2005 with a stable outlook.
• Accounting Changes: The company must adopt SFAS 123R (Share-Based Payment) effective January 1, 2006, which is expected to have a material effect on reported net income by requiring fair value recognition of stock-based compensation.
• Guidance: Management expects the effective tax rate for 2005 to be approximately 39.4%. No specific revenue or earnings guidance for the full year was provided in this text.

Investor Verification Checklist

• IRS LIFO Dispute: Verify the status of the appeal regarding the $40.9 million potential tax deficiency and the likelihood of a cash outflow.
• Hurricane Claims: Monitor the resolution of insurance claims related to business interruption and increased costs from Hurricanes Katrina and Rita.
• Acquisition Integration: Assess the performance of the Access Diabetic Supply acquisition and its contribution to gross margins versus the increased SG&A burden.
• Capital Expenditures: Track the completion and cost of the new corporate headquarters construction.
• Stock-Based Compensation: Review the impact of the upcoming SFAS 123R adoption on future earnings per share.